Bicycle Therapeutics plc Share-based Payment Arrangement, Expense
Bicycle Therapeutics plc (BCYC) reported Share-based Payment Arrangement, Expense of $6.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-07-30
- Bicycle Therapeutics plc share-based payment arrangement, expense for the quarter ending 2026-06-30 was $6.40M, a 32.13% decline year-over-year.
- Bicycle Therapeutics plc share-based payment arrangement, expense for the quarter ending 2026-03-31 was $6.93M, a 27.85% decline year-over-year.
- Bicycle Therapeutics plc share-based payment arrangement, expense for the quarter ending 2025-12-31 was $11.65M, a 12.77% increase year-over-year.
- Bicycle Therapeutics plc share-based payment arrangement, expense for the quarter ending 2025-09-30 was $8.77M, a 4.68% decline year-over-year.
- Bicycle Therapeutics plc share-based payment arrangement, expense for fiscal 2025 was $39.46M, a 3.63% increase from fiscal 2024.
- Bicycle Therapeutics plc share-based payment arrangement, expense for fiscal 2024 was $38.08M, a 17.26% increase from fiscal 2023.
- Bicycle Therapeutics plc share-based payment arrangement, expense for fiscal 2023 was $32.48M, a 21.28% increase from fiscal 2022.
- Bicycle Therapeutics plc share-based payment arrangement, expense for fiscal 2022 was $26.78M, a 121.63% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.40M 10-Q · filed 2026-07-30 | $13.33M 10-Q · filed 2026-07-30 | $24.99M derived: sum of 3 quarters · filed 2026-07-30 | $33.76M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $6.93M 10-Q · filed 2026-04-30 | $18.58M derived: sum of 2 quarters · filed 2026-04-30 | $27.35M derived: sum of 3 quarters · filed 2026-04-30 | $36.79M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $20.42M derived: sum of 2 quarters · filed 2026-03-17 | $29.86M derived: sum of 3 quarters · filed 2026-07-30 | $39.46M 10-K · filed 2026-03-17 |
| 2025-09-30 | $8.77M 10-Q · filed 2025-10-30 | $18.21M derived: sum of 2 quarters · filed 2026-07-30 | $27.81M 10-Q · filed 2025-10-30 | $38.14M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $9.44M 10-Q · filed 2026-07-30 | $19.04M 10-Q · filed 2026-07-30 | $29.37M derived: sum of 3 quarters · filed 2026-07-30 | $38.58M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $9.61M 10-Q · filed 2026-04-30 | $19.94M derived: sum of 2 quarters · filed 2026-04-30 | $29.14M derived: sum of 3 quarters · filed 2026-04-30 | $38.40M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $10.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $19.54M derived: sum of 2 quarters · filed 2026-03-17 | $28.80M derived: sum of 3 quarters · filed 2026-03-17 | $38.08M 10-K · filed 2026-03-17 |
| 2024-09-30 | $9.20M 10-Q · filed 2025-10-30 | $18.47M derived: sum of 2 quarters · filed 2025-10-30 | $27.75M 10-Q · filed 2025-10-30 | $35.56M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $9.26M 10-Q · filed 2025-08-08 | $18.55M 10-Q · filed 2025-08-08 | $26.36M derived: sum of 3 quarters · filed 2026-03-17 | $33.79M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $9.28M 10-Q · filed 2025-05-01 | $17.09M derived: sum of 2 quarters · filed 2026-03-17 | $24.52M derived: sum of 3 quarters · filed 2026-03-17 | $32.72M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $15.24M derived: sum of 2 quarters · filed 2026-03-17 | $23.43M derived: sum of 3 quarters · filed 2026-03-17 | $32.48M 10-K · filed 2026-03-17 |
| 2023-09-30 | $7.43M 10-Q · filed 2024-10-31 | $15.62M derived: sum of 2 quarters · filed 2024-10-31 | $24.66M 10-Q · filed 2024-10-31 | $30.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $8.19M 10-Q · filed 2024-08-06 | $17.23M 10-Q · filed 2024-08-06 | $22.77M derived: sum of 3 quarters · filed 2025-02-25 | $28.14M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $9.04M 10-Q · filed 2024-05-02 | $14.58M derived: sum of 2 quarters · filed 2025-02-25 | $19.95M derived: sum of 3 quarters · filed 2025-02-25 | $25.62M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $10.91M derived: sum of 2 quarters · filed 2025-02-25 | $16.58M derived: sum of 3 quarters · filed 2025-02-25 | $26.78M 10-K · filed 2025-02-25 |
| 2022-09-30 | $5.37M 10-Q · filed 2023-11-02 | $11.04M derived: sum of 2 quarters · filed 2023-11-02 | $21.24M 10-Q · filed 2023-11-02 | $24.24M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $5.67M 10-Q · filed 2023-08-03 | $15.87M 10-Q · filed 2023-08-03 | $18.87M derived: sum of 3 quarters · filed 2024-02-20 | $21.56M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $10.20M 10-Q · filed 2023-05-04 | $13.20M derived: sum of 2 quarters · filed 2024-02-20 | $15.88M derived: sum of 3 quarters · filed 2024-02-20 | $18.46M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $5.69M derived: sum of 2 quarters · filed 2024-02-20 | $8.26M derived: sum of 3 quarters · filed 2024-02-20 | $12.08M 10-K · filed 2024-02-20 |
| 2021-09-30 | $2.69M 10-Q · filed 2022-11-03 | $5.26M derived: sum of 2 quarters · filed 2022-11-03 | $9.08M 10-Q · filed 2022-11-03 | $10.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.58M 10-Q · filed 2022-08-04 | $6.40M 10-Q · filed 2022-08-04 | $7.96M derived: sum of 3 quarters · filed 2023-02-28 | $9.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $3.82M 10-Q · filed 2022-05-05 | $5.38M derived: sum of 2 quarters · filed 2023-02-28 | $6.89M derived: sum of 3 quarters · filed 2023-02-28 | $8.21M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.07M derived: sum of 2 quarters · filed 2023-02-28 | $4.39M derived: sum of 3 quarters · filed 2023-02-28 | $6.51M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.51M 10-Q · filed 2021-11-04 | $2.83M derived: sum of 2 quarters · filed 2021-11-04 | $4.95M 10-Q · filed 2021-11-04 | $6.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $1.32M 10-Q · filed 2021-08-05 | $3.44M 10-Q · filed 2021-08-05 | $4.52M derived: sum of 3 quarters · filed 2022-03-01 | $5.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.12M 10-Q · filed 2021-05-06 | $3.20M derived: sum of 2 quarters · filed 2022-03-01 | $4.02M derived: sum of 3 quarters · filed 2022-03-01 | $4.93M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.90M derived: sum of 2 quarters · filed 2022-03-01 | $2.81M derived: sum of 3 quarters · filed 2022-03-01 | $3.08M 10-K · filed 2022-03-01 |
| 2019-09-30 | $819.00K 10-Q · filed 2020-11-05 | $1.72M derived: sum of 2 quarters · filed 2020-11-05 | $2.00M 10-Q · filed 2020-11-05 | $2.21M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $905.00K 10-Q · filed 2020-08-05 | $1.18M 10-Q · filed 2020-08-05 | $1.39M derived: sum of 3 quarters · filed 2021-03-11 | $1.62M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | $276.00K 10-Q · filed 2020-05-07 | $483.00K derived: sum of 2 quarters · filed 2021-03-11 | $713.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.05M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $437.00K derived: sum of 2 quarters · filed 2021-03-11 | $772.00K derived: sum of 3 quarters · filed 2021-03-11 | $1.02M 10-K · filed 2021-03-11 |
| 2018-09-30 | $230.00K 10-Q · filed 2019-11-07 | $565.00K derived: sum of 2 quarters · filed 2019-11-07 | $816.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $335.00K 10-Q · filed 2019-08-08 | $587.00K 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $515.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |